Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the warrants were convertable @ $1.50 per. If no cash then what did they provide of value. they HAD TO PROVIDE SOMETHING!
NO free shares
If NO CASH then what? agreement to pay all or part of product development and trial costs? THEY GOT SOMETHING
Advaxis: an enigna wrapped in a mystery
unclear whether cash payment is involved $1.50?? per
purpose: to position the firm for future, NEAR TERM, collaboration, financing...
purpose of this exchange- to aid upcoming financing? read new filing
limits for 15 days an investors' ability to sell these new shares
new SEC filing. exchange of 12.8 mill new warrants for 12.8 mill shares at %1.50 per.(as i understand it)
expectations (at the moment), real or imaginary
up premarket on decentd volume
is the share price recovery real?
next two days will be revealing
how can i be sure?
pushing 14 mill shares, still another push to go at the close? end at $.70?
Parabolic second derivative?
3,000,000 shares and counting
could close at $.50 today tomorrow?
pokes at both ends: open and close?
there are three THREE other formulations which Advaxis licensed to Aratana. COMPLETE SILENCE FROM BOTH AS TO WHAT THEY ARE FOR AND WHAT, IF ANYTHING, IS HAPPENING WITH THEM
puzzles me why PETX has slow walked AT-014. They are about a year behind where they should be. Did not realize a final safety and efficacy study was required?
Ken stopped the bleeding
lets see if there is follow through. March 31-April 1? If positive news re AT-014 is forthcoming(and it really should be shortly) I believe we are $1+
approval means sales, means revenue, means increase in market cap
PETX mgt says in Q report that they seek income. Stock down to $3s. They need AT-014 as much as Advaxis does
Apparently no update from PETX re AT-014. Inquired why?
paid earlier, recognized for accounting purposes now
do not think this is the case. announcement I read said first positive income report in 19 quarters. the original partnership? $25 mill recognized earlier, now $15?
I take this AMs report from Advaxis as a positive. PETX reports today after hrs. news re AT-014 expected
I do not believe they are drawing into an inside straight
says the study is still enrolling. this study involves dogs who are not candidates for amputation. Is this still another study? So far no mean survival rate compared to 8 months for untreated and no significant adverse effects.
maybe just poor management. I for one would prefer a pharma experienced CEO to an attorney any day of the week
Aratana licensed three other drugs as well. Neither they nor Advaxis have ever revealed what they are for. Big Secret. Perhaps PETX licensed them to bury
Positive news March 12 from PETX could push pps above $1
March 12 PETX reports Q4 and is expected to provide update on AT-014
advaxis is undervalued from the perspective of its potential future earnings
70 mill shares give or take but approx 25 mill voted. gives the edge to tutes and mgt
Zacks, CVI as well
March 12. not so far away. both Advaxis and Aratana Theraputics report